INVA vs PATH · P/E 3.6, rev $358.7M vs P/E 19, rev $1.61B
Innoviva Inc (INVA) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Innoviva Inc (INVA) is a biotechnology company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported INVA revenue for 2024-12-31 was $358.7M. Net income was $23.4M. Revenue was up 15.5% from 2023-12-31 to 2024-12-31. INVA currently screens at market cap $1.66B and trailing P/E 3.6.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
INVA currently screens at market cap $1.66B and trailing P/E 3.6. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the INVA and PATH stock pages for the full models.
Not investment advice.